The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or “the Company”) (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 20, 2018.

LOS ANGELES, CA / ACCESSWIRE / November 16, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.

Dependable dividend stocks that routinely grow their payouts are welcome in any environment. But they seem especially attractive nowadays. Stock market volatility is back with a vengeance. The Dow Jones Industrial Average went from powering ahead to an all-time high of 26,828 on Oct. 3 to losing 8% in the span of about three weeks. These kinds of rocky markets tend to give investors motion sickness. But they can add a dose of Dramamine to their portfolios - in the form of reliable dividend-growth stocks. "Dividend growers, which tend to be quality companies, have generally shown greater resilience in unsteady markets and could address concerns about dividend stocks in a rising-rate environment," write Tianyin Cheng, director of strategy and ESG Indices at S&P Dow Jones Indices; and Vinit Srivastava, head of strategy and ESG indices at S&P Dow Jones Indices. "This argument applies to not only to the U.S. large-cap space, but it also extends to small- and mid-cap segments and international markets." Dividend stocks - both at home and abroad - with long track records of rock-solid rising payments tend to generate superior returns over long periods of time and can help investors weather shorter periods of market turbulence. This is a look at the most reliable long-term dividend stocks in the world. Dubbed the "Dividend Aristocrats," they have raised dividends for at least five straight years (Canadian firms), 10 years (E.U.-based firms) or 25 years (U.S. companies). Such stocks provide reliable and rising income streams - and a sense of security that will help you sleep better at night. We've listed them here alphabetically; take a look. SEE ALSO: 25 Stocks Every Retiree Should Own

NEW YORK, NY / ACCESSWIRE / November 16, 2018 / WeissLawLLP, a national class action and shareholders' rights law firm with offices in New York, Los Angeles, and Atlanta, announces an investigation of AbbVie Inc. ("AbbVie" or the "Company") (ABBV). On September 18, 2018, a Bloomberg report revealed that the State of California had filed a lawsuit against the Company for its engagement in a kickback scheme.

For investors who are seeking exposure to the cannabis industry but consider pure-play companies too risky, there are many other interesting investment opportunities. Pharma and biotech companies have ...

NEW YORK, NY / ACCESSWIRE / November 15, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc. ("AbbVie" or the "Company") (ABBV) of the November 20, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in AbbVie stock or options between October 25, 2013 and September 18, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ABBV.There is no cost or obligation to you.

Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (''AbbVie'' or the ''Company'') (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the ''Class Period''). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.